Dray A, Nunan L, Wire W
Br J Pharmacol. 1985 Jul;85(3):717-26. doi: 10.1111/j.1476-5381.1985.tb10569.x.
The in vivo effects of a number of opioid agonists and antagonists were studied on the spontaneous reflex contractions of the urinary bladder recorded isometrically in the rat anesthetized with urethane. All substances were administered into the central nervous system by the intracereboventricular (i.c.v.) or spinal intrathecal (i.t.) route. The conformationally restricted enkephalin analogues [2-D-penicillamine, 5-L-cysteine] enkephalin (DPLCE), [2-D-penicillamine, 5-L-penicillamine] enkephalin (DPLPE) and [2-D-penicillamine, 5-D-penicillamine] enkephalin (DPDPE) produced dose-related inhibition of reflex bladder contractions when administered by the i.c.v. or i.t. route. Both the novel delta-opioid receptor antagonist ICI 154,129 (200-600 micrograms) [N,N-bisallyl-Tyr-Gly-Gly-Psi-(CH2S)-Phe-Leu-OH) and ICI 174,864 (1-3 micrograms) [N,N-dially-Tyr-Aib-Aib-Phe-Leu-OH: Aib = alpha-aminoisobutyric acid] attenuated or abolished the effects of DPLCE, DPLPE and DPDPE when administered by the i.c.v. or i.t. route. The antagonism observed was selective since the equipotent inhibition produced by the mu-opioid receptor agonist [D-Ala2, Me-Phe4, Gly(ol)5] enkephalin (DAGO) was unaffected. Overall, ICI 154,129 was considerably weaker than ICI 174,864 and both antagonists inhibited bladder activity at doses higher than those required to demonstrate delta-receptor antagonism. Further studies of the agonistic effect of ICI 174,864 showed that it was insensitive to low doses of naloxone (2 micrograms, i.c.v. or i.t.) but could be abolished by higher (10-15 micrograms) doses of naloxone. These observations suggested that the agonistic effect of ICI 174,864 was not mediated by mu-opioid receptor. beta-Endorphin (0.2-1.0 micrograms, i.c.v.) inhibited bladder contractions but following recovery from this effect, appeared to prevent the expression of delta-receptor antagonism by ICI 174,864. In addition a previously subthreshold dose of ICI 174,864 now exhibited marked agonistic activity. The inhibitory effect of a submaximal dose of DPDPE was also potentiated by beta-endorphin under these circumstances. These observations suggest that supra-spinal and spinal delta-opioid receptors are involved in the opioid-mediated inhibition of reflex bladder contractions in the rat. Moreover beta-endorphin may be important in regulating central delta-opioid receptors.
研究了多种阿片类激动剂和拮抗剂对在用氨基甲酸乙酯麻醉的大鼠中,通过等长记录的膀胱自发反射收缩的体内作用。所有物质均通过脑室内(i.c.v.)或脊髓鞘内(i.t.)途径注入中枢神经系统。构象受限的脑啡肽类似物[2-D-青霉胺,5-L-半胱氨酸]脑啡肽(DPLCE)、[2-D-青霉胺,5-L-青霉胺]脑啡肽(DPLPE)和[2-D-青霉胺,5-D-青霉胺]脑啡肽(DPDPE)通过i.c.v.或i.t.途径给药时,可产生与剂量相关的膀胱反射收缩抑制作用。新型δ-阿片受体拮抗剂ICI 154,129(200-600微克)[N,N-双烯丙基-Tyr-Gly-Gly-Psi-(CH2S)-Phe-Leu-OH]和ICI 174,864(1-3微克)[N,N-二烯丙基-Tyr-Aib-Aib-Phe-Leu-OH:Aib = α-氨基异丁酸]通过i.c.v.或i.t.途径给药时,可减弱或消除DPLCE、DPLPE和DPDPE的作用。观察到的拮抗作用具有选择性,因为μ-阿片受体激动剂[D-Ala2,Me-Phe4,Gly(ol)5]脑啡肽(DAGO)产生的等效抑制作用不受影响。总体而言,ICI 154,129比ICI 174,864弱得多,两种拮抗剂在高于显示δ-受体拮抗作用所需剂量时均抑制膀胱活动。对ICI 174,864激动作用的进一步研究表明,它对低剂量的纳洛酮(2微克,i.c.v.或i.t.)不敏感,但可被较高剂量(10-15微克)的纳洛酮消除。这些观察结果表明,ICI 174,864的激动作用不是由μ-阿片受体介导的。β-内啡肽(0.2-1.0微克,i.c.v.)抑制膀胱收缩,但在这种作用恢复后,似乎可阻止ICI 174,864的δ-受体拮抗作用的表达。此外,先前阈下剂量的ICI 174,864现在表现出明显的激动活性。在这些情况下,β-内啡肽也增强了次最大剂量DPDPE的抑制作用。这些观察结果表明,脊髓上和脊髓的δ-阿片受体参与了阿片介导的大鼠膀胱反射收缩的抑制。此外,β-内啡肽可能在调节中枢δ-阿片受体方面很重要。